AUTOMATIC DATA PROCESSING INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AUTOMATIC DATA PROCESSING INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $20.56B | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | $19.20B | Aug 6, 2025 |
| FY2025 | Jun 30, 2023 | $18.01B | Aug 6, 2025 |
| FY2024 | Jun 30, 2022 | $16.50B | Aug 7, 2024 |
| FY2023 | Jun 30, 2021 | $15.01B | Aug 3, 2023 |
| FY2020 | Jun 30, 2020 | $3.38B | Aug 5, 2020 |
| FY2020 | Mar 31, 2020 | $4.05B | Aug 5, 2020 |
| FY2020 | Dec 31, 2019 | $3.67B | Aug 5, 2020 |
| FY2020 | Sep 30, 2019 | $3.50B | Aug 5, 2020 |
| FY2020 | Jun 30, 2019 | $3.48B | Aug 5, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $20.56B | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | $19.20B | Aug 6, 2025 |
| FY2025 | Jun 30, 2023 | $18.01B | Aug 6, 2025 |
| FY2024 | Jun 30, 2022 | $16.50B | Aug 7, 2024 |
| FY2023 | Jun 30, 2021 | $15.01B | Aug 3, 2023 |
| FY2022 | Jun 30, 2020 | $14.59B | Aug 3, 2022 |
| FY2021 | Jun 30, 2019 | $14.11B | Aug 4, 2021 |
| FY2020 | Jun 30, 2018 | $13.27B | Aug 5, 2020 |
| FY2019 | Jun 30, 2017 | $12.37B | Aug 9, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jun 30, 2018 | $8.99B | Aug 3, 2018 |
| FY2018 | Jun 30, 2017 | $8.52B | Aug 3, 2018 |
| FY2018 | Jun 30, 2016 | $8.23B | Aug 3, 2018 |
| FY2017 | Jun 30, 2015 | $7.93B | Aug 4, 2017 |
| FY2016 | Jun 30, 2014 | $7.60B | Aug 5, 2016 |
| FY2015 | Jun 30, 2013 | $7.06B | Aug 7, 2015 |
| FY2014 | Jun 30, 2012 | $8.34B | Aug 8, 2014 |
| FY2013 | Jun 30, 2011 | $7.76B | Aug 19, 2013 |
| FY2012 | Jun 30, 2010 | $7.08B | Aug 20, 2012 |
| FY2011 | Jun 30, 2009 | $7.05B | Aug 24, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jun 30, 2020 | $1.31B | Aug 5, 2020 |
| FY2020 | Mar 31, 2020 | $1.81B | Aug 5, 2020 |
| FY2020 | Dec 31, 2019 | $1.58B | Aug 5, 2020 |
| FY2020 | Sep 30, 2019 | $1.45B | Aug 5, 2020 |
| FY2020 | Jun 30, 2019 | $1.48B | Aug 5, 2020 |
| FY2020 | Mar 31, 2019 | $1.74B | Aug 5, 2020 |
| FY2020 | Dec 31, 2018 | $1.49B | Aug 5, 2020 |
| FY2020 | Sep 30, 2018 | $1.38B | Aug 5, 2020 |
| FY2019 | Jun 30, 2018 | $1.37B | Aug 9, 2019 |
| FY2019 | Mar 31, 2018 | $1.62B | Aug 9, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $4.08B | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | $3.75B | Aug 6, 2025 |
| FY2025 | Jun 30, 2023 | $3.41B | Aug 6, 2025 |
| FY2024 | Jun 30, 2022 | $2.95B | Aug 7, 2024 |
| FY2023 | Jun 30, 2021 | $2.60B | Aug 3, 2023 |
| FY2020 | Jun 30, 2020 | $411.50M | Aug 5, 2020 |
| FY2020 | Mar 31, 2020 | $820.90M | Aug 5, 2020 |
| FY2020 | Dec 31, 2019 | $651.60M | Aug 5, 2020 |
| FY2020 | Sep 30, 2019 | $582.40M | Aug 5, 2020 |
| FY2020 | Jun 30, 2019 | $475.50M | Aug 5, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $988.60M | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | $955.70M | Aug 6, 2025 |
| FY2025 | Jun 30, 2023 | $844.80M | Aug 6, 2025 |
| FY2024 | Jun 30, 2022 | $798.60M | Aug 7, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $4.05B | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | $3.78B | Aug 6, 2025 |
| FY2025 | Jun 30, 2023 | $3.55B | Aug 6, 2025 |
| FY2024 | Jun 30, 2022 | $3.23B | Aug 7, 2024 |
| FY2023 | Jun 30, 2021 | $3.04B | Aug 3, 2023 |
| FY2022 | Jun 30, 2020 | $3.00B | Aug 3, 2022 |
| FY2021 | Jun 30, 2019 | $3.06B | Aug 4, 2021 |
| FY2020 | Jun 30, 2018 | $2.96B | Aug 5, 2020 |
| FY2019 | Jun 30, 2017 | $2.77B | Aug 9, 2019 |
| FY2018 | Jun 30, 2016 | $2.64B | Aug 3, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $4.94B | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | $4.16B | Aug 6, 2025 |
| FY2025 | Jun 30, 2023 | $4.21B | Aug 6, 2025 |
| FY2024 | Jun 30, 2022 | $3.10B | Aug 7, 2024 |
| FY2023 | Jun 30, 2021 | $3.09B | Aug 3, 2023 |
| FY2022 | Jun 30, 2020 | $3.03B | Aug 3, 2022 |
| FY2021 | Jun 30, 2019 | $2.69B | Aug 4, 2021 |
| FY2020 | Jun 30, 2018 | $2.52B | Aug 5, 2020 |
| FY2019 | Jun 30, 2017 | $2.13B | Aug 9, 2019 |
| FY2018 | Jun 30, 2016 | $1.90B | Aug 3, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $53.37B | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | $54.36B | Aug 6, 2025 |
| FY2025 | Jun 30, 2023 | $50.97B | Aug 6, 2025 |
| FY2024 | Jun 30, 2022 | $63.07B | Aug 7, 2024 |
| FY2023 | Jun 30, 2021 | $48.77B | Aug 3, 2023 |
| FY2022 | Jun 30, 2020 | $39.17B | Aug 3, 2022 |
| FY2021 | Jun 30, 2019 | $41.89B | Aug 4, 2021 |
| FY2020 | Jun 30, 2018 | $38.85B | Aug 5, 2020 |
| FY2019 | Jun 30, 2017 | $38.89B | Aug 9, 2019 |
| FY2017 | Jun 30, 2016 | $43.67B | Aug 4, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $47.18B | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | $49.82B | Aug 6, 2025 |
| FY2024 | Jun 30, 2023 | $47.46B | Aug 7, 2024 |
| FY2023 | Jun 30, 2022 | $59.84B | Aug 3, 2023 |
| FY2022 | Jun 30, 2021 | $43.10B | Aug 3, 2022 |
| FY2021 | Jun 30, 2020 | $33.41B | Aug 4, 2021 |
| FY2020 | Jun 30, 2019 | $36.49B | Aug 5, 2020 |
| FY2019 | Jun 30, 2018 | $34.11B | Aug 9, 2019 |
| FY2018 | Jun 30, 2017 | $33.20B | Aug 3, 2018 |
| FY2017 | Jun 30, 2016 | $39.19B | Aug 4, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $6.19B | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | $4.55B | Aug 6, 2025 |
| FY2024 | Jun 30, 2023 | $3.51B | Aug 7, 2024 |
| FY2023 | Jun 30, 2022 | $3.23B | Aug 3, 2023 |
| FY2022 | Jun 30, 2021 | $5.67B | Aug 3, 2022 |
| FY2021 | Jun 30, 2020 | $5.75B | Aug 4, 2021 |
| FY2020 | Jun 30, 2019 | $5.40B | Aug 5, 2020 |
| FY2019 | Jun 30, 2018 | $4.74B | Aug 9, 2019 |
| FY2018 | Jun 30, 2017 | $3.98B | Aug 3, 2018 |
| FY2017 | Jun 30, 2016 | $4.48B | Aug 4, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.27B | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | $2.35B | Aug 6, 2025 |
| FY2025 | Jun 30, 2023 | $2.34B | Aug 6, 2025 |
| FY2024 | Jun 30, 2022 | $2.30B | Aug 7, 2024 |
| FY2023 | Jun 30, 2021 | $2.34B | Aug 3, 2023 |
| FY2022 | Jun 30, 2020 | $2.31B | Aug 3, 2022 |
| FY2021 | Jun 30, 2019 | $2.32B | Aug 4, 2021 |
| FY2020 | Jun 30, 2018 | $2.24B | Aug 5, 2020 |
| FY2019 | Jun 30, 2017 | $1.74B | Aug 9, 2019 |
| FY2018 | Jun 30, 2016 | $1.68B | Aug 3, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $25.24B | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | $23.62B | Aug 6, 2025 |
| FY2024 | Jun 30, 2023 | $22.12B | Aug 7, 2024 |
| FY2023 | Jun 30, 2022 | $20.70B | Aug 3, 2023 |
| FY2022 | Jun 30, 2021 | $19.45B | Aug 3, 2022 |
| FY2021 | Jun 30, 2020 | $18.44B | Aug 4, 2021 |
| FY2020 | Jun 30, 2019 | $17.50B | Aug 5, 2020 |
| FY2019 | Jun 30, 2018 | $16.55B | Aug 9, 2019 |
| FY2018 | Jun 30, 2017 | $14.73B | Aug 3, 2018 |
| FY2017 | Jun 30, 2016 | $14.00B | Aug 4, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.35B | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | $2.91B | Aug 6, 2025 |
| FY2025 | Jun 30, 2023 | $2.08B | Aug 6, 2025 |
| FY2024 | Jun 30, 2022 | $1.44B | Aug 7, 2024 |
| FY2023 | Jun 30, 2021 | $2.58B | Aug 3, 2023 |
| FY2022 | Jun 30, 2020 | $1.91B | Aug 3, 2022 |
| FY2021 | Jun 30, 2019 | $1.95B | Aug 4, 2021 |
| FY2020 | Jun 30, 2018 | $2.17B | Aug 5, 2020 |
| FY2019 | Jun 30, 2017 | $2.78B | Aug 9, 2019 |
| FY2018 | Jun 30, 2016 | $3.19B | Aug 3, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Jun 30, 2011 | $37.00M | Aug 24, 2011 |
| FY2010 | Jun 30, 2010 | $42.60M | Aug 25, 2010 |
| FY2010 | Jun 30, 2009 | $45.50M | Aug 25, 2010 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 10 | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | 9 | Aug 6, 2025 |
| FY2025 | Jun 30, 2023 | 8 | Aug 6, 2025 |
| FY2024 | Jun 30, 2022 | 7 | Aug 7, 2024 |
| FY2023 | Jun 30, 2021 | 6 | Aug 3, 2023 |
| FY2022 | Jun 30, 2020 | 5 | Aug 3, 2022 |
| FY2021 | Jun 30, 2019 | 5 | Aug 4, 2021 |
| FY2020 | Jun 30, 2018 | 4 | Aug 5, 2020 |
| FY2019 | Jun 30, 2017 | 3 | Aug 9, 2019 |
| FY2018 | Jun 30, 2016 | 3 | Aug 3, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 9 | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | 9 | Aug 6, 2025 |
| FY2025 | Jun 30, 2023 | 8 | Aug 6, 2025 |
| FY2024 | Jun 30, 2022 | 7 | Aug 7, 2024 |
| FY2023 | Jun 30, 2021 | 6 | Aug 3, 2023 |
| FY2022 | Jun 30, 2020 | 5 | Aug 3, 2022 |
| FY2021 | Jun 30, 2019 | 5 | Aug 4, 2021 |
| FY2020 | Jun 30, 2018 | 4 | Aug 5, 2020 |
| FY2019 | Jun 30, 2017 | 3 | Aug 9, 2019 |
| FY2018 | Jun 30, 2016 | 3 | Aug 3, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 405.30M | Aug 6, 2025 |
| FY2025 | Jun 30, 2024 | 408.10M | Aug 6, 2025 |
| FY2024 | Jun 30, 2023 | 412.10M | Aug 7, 2024 |
| FY2023 | Jun 30, 2022 | 416.10M | Aug 3, 2023 |
| FY2022 | Jun 30, 2021 | 423.70M | Aug 3, 2022 |
| FY2021 | Jun 30, 2020 | 429.90M | Aug 4, 2021 |
| FY2020 | Jun 30, 2019 | 434.20M | Aug 5, 2020 |
| FY2019 | Jun 30, 2018 | 438.80M | Aug 9, 2019 |
| FY2018 | Jun 30, 2017 | 445.00M | Aug 3, 2018 |
| FY2017 | Jun 30, 2016 | 455.70M | Aug 4, 2017 |